Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

January 03, 2024 16:01 ET | Source: BioCryst Pharmaceuticals, Inc.

BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

RESEARCH TRIANGLE PARK, N.C., Jan. 03, 2024 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the compensation committee of BioCryst’s board of directors granted...
January 03, 2024 07:00 ET | Source: BioCryst Pharmaceuticals, Inc.

BioCryst to Present at 42nd Annual J.P. Morgan Healthcare Conference

RESEARCH TRIANGLE PARK, N.C., Jan. 03, 2024 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company will present at the 42nd Annual J.P. Morgan Healthcare...
December 19, 2023 07:00 ET | Source: BioCryst Pharmaceuticals, Inc.

BioCryst Announces Publication of Data from Open-label Extension of the APeX-2 Pivotal Trial of ORLADEYO® (berotralstat)

RESEARCH TRIANGLE PARK, N.C., Dec. 19, 2023 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that data from the open-label extension (OLE) of the APeX-2 trial of...
December 05, 2023 16:01 ET | Source: BioCryst Pharmaceuticals, Inc.

BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

RESEARCH TRIANGLE PARK, N.C., Dec. 05, 2023 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the compensation committee of BioCryst’s board of directors granted...
November 29, 2023 07:00 ET | Source: BioCryst Pharmaceuticals, Inc.

BioCryst Announces Approval of ORLADEYO® (berotralstat) by the National Administration of Drugs, Foods, and Medical Devices (ANMAT) in Argentina

RESEARCH TRIANGLE PARK, N.C., Nov. 29, 2023 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the National Administration of Drugs, Foods, and Medical Devices...
November 21, 2023 16:01 ET | Source: BioCryst Pharmaceuticals, Inc.

BioCryst to Present at Upcoming Investor Conferences

RESEARCH TRIANGLE PARK, N.C., Nov. 21, 2023 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company will present at the 6th Annual Evercore ISI HealthCONx...
November 21, 2023 07:00 ET | Source: BioCryst Pharmaceuticals, Inc.

BioCryst Launches ORLADEYO® (berotralstat) in Spain

RESEARCH TRIANGLE PARK, N.C., Nov. 21, 2023 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the Spanish Ministry for Health (Ministerio de Sanidad) has granted...
November 10, 2023 07:00 ET | Source: BioCryst Pharmaceuticals, Inc.

BioCryst Presents New Real-world Data Showing Reduced Attack Rates in Patients with HAE with Normal C1-inhibitor Following Long-term Treatment with ORLADEYO® (berotralstat)

RESEARCH TRIANGLE PARK, N.C., Nov. 10, 2023 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced new analyses of real-world use of oral, once-daily ORLADEYO®...
November 06, 2023 16:01 ET | Source: BioCryst Pharmaceuticals, Inc.

BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

RESEARCH TRIANGLE PARK, N.C., Nov. 06, 2023 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the compensation committee of BioCryst’s board of directors granted...
November 03, 2023 12:03 ET | Source: BioCryst Pharmaceuticals, Inc.

BioCryst R&D Day Highlights New Diversified Pipeline of First-in-Class/Best-in-Class Therapies with Five Programs Expected in Clinical Development in Next 24 Months

Company builds on deep structure-based drug design capabilities to add protein therapeutics to pipeline: BCX17725 for Netherton syndrome — entering clinic in 2H 2024Bifunctional fusion protein...

keyboard_arrow_left Previous Page

Next Page keyboard_arrow_right